Caller asked about NKTR and mentioned pipeline and buyout possibilities. Cramer said he hadn't looked at NKTR in years and wasn't up to date on it. He said he would do a full drilldown on the company. Expect a detailed report from him in the next couple of days.
NKTR's most notorious shorter, Shkreli, is in the news today because of his biotech M&A activities. See below. A poster on Biotech Values noted that Shkrelie used to work with Cramer. Let's hope Cramer's "dirlldown" doesn't consist of a review of Martin#$%$ pieces on NKTR (or maybe we should, because it could prompt Cramer to look much more closely to find out why Martin has been so wrong).
Martin Shkreli's biotech outfit Retrophin has proposed a buyout of struggling Transcept Pharmaceuticals ($TSPT) for $4 per share, but the management of Point Richmond, CA-based Transcept has undertaken a "poison pill" action to keep acquirers at bay.
Read more: Wearing biotech hat, hedge fund vet Shkreli shakes the gate at Transcept - FierceBiotech
I see that the ymb abusive language program decided to correct my Martin"["s"] plus "hit" pieces into gibberish. The program's interpretation is actually a more apt description of Martin's work than my original characterization.
He can help or hurt. Cramer can provide timing to buy in. With the FDA acceptance NKTR 118 he may say wait as an entrant point. In Q4 we have several key data releases. No approval except NKTR 102 OC maybe. I am thinking NKTR 102 BC is the prime approval and Phase IIs are used for off label.